TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has given written informed consent~2. Patient is 18 years or older~3. Patient has histologically confirmed prostate cancer~4. Patient has a serum prostate-specific antigen (PSA) level at screening \>2 ng/mL~5. The prostate size is \>30 cubic centimetres (cc), measured by TRUS~6. Patient has had a bone-scan within 12 weeks before inclusion~7. Patient must be able to undergo transrectal examinations~8. Patient has an estimated life expectancy of at least 12 months~Exclusion Criteria:~1. Any previous treatments for prostate cancer~2. Previous trans-urethral resection of the prostate (TURP)~3. Is not considered a candidate for medical castration~4. Use of urethral catheter~5. Is currently treated with a 5-alpha reductase inhibitor~6. Is currently treated with an alpha-adrenoceptor antagonist~7. Treatment with botulinum toxin A (Botox)~8. Require radiotherapy during the trial~9. History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema~10. Hypersensitivity towards any component of the investigational products or excipients~11. Previous history or presence of another malignancy~12. A clinically significant disorder~13. A corrected QT interval over 450 msec~14. Mental incapacity or language barrier precluding adequate understanding or co-operation~15. Receipt of an investigational drug within the last 28 days proceeding screening~16. Previous participation in any degarelix trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with with no medical problems (n=15) and individuals with primary hyperparathyroidism (n=30)~* normal blood pressure or stage 1 hypertension that is either untreated, or adequately treated with a single anti-hypertensive medication.~* Age \>18 years and \<80 years~* Estimated GFR \> 60ml/min~Exclusion Criteria:~* Chronic Kidney Disease or eGFR\<60~* Stage 2 or Stage 3 hypertension or the use of more than 1 antihypertensive drug~* Type 2 Diabetes Mellitus that is not controlled by diet or Metformin alone or with a Hemoglobin A1c \>7.5%~* History of liver failure~* History of heart failure~* The use of typical or atypical antipsychotic medications or lithium.~* Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that are treated with prescribed doses of NSAIDs or glucocorticoids~* The use of prescribed doses of potassium supplements.~* Illness requiring overnight hospitalization in the past 6 months~* Active tobacco or recreational drug use~* Pregnancy or current breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- lisinopril (Type: EXPERIMENTAL): Lisinopril - open-label, 2.5-40mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Minimum of 3 months documented history of asthma, diagnosed according to the American Thoracic Society (ATS) definition.~* Prescribed inhaled GCS at a dose of ≥320 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.~Exclusion Criteria:~* Use of any b-blocking agent, including eye-drops.~* Use of oral GCS as maintenance treatment.~* Known or suspected hypersensitivity to study therapy or excipients.~* A history of smoking ≥ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years and below 80 years at the time of signing informed consent~* Subjects diagnosed type 2 diabetes mellitus and treated with metformin monotherapy at a stable dose of at least 1500 mg daily or maximum tolerated dose above or equal to 1000 mg daily for at least 60 days prior to screening~* HbA1c 7.0-10.0% (both inclusive)~* Body mass index below or equal to 45.0 kg/m\^2~Exclusion Criteria:~* Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 60 days prior to screening. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Any chronic disorder or severe disease which at the discretion of the investigator might jeopardise subject's safety or compliance with the protocol~* Screening calcitonin value above or equal to 50 ng/l~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2~* Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)~* Any contraindications to liraglutide, sitagliptin or metformin according to local labelling

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 1.8 mg + metformin (Type: EXPERIMENTAL): 2-week screening period, 26-week treatment duration, and a 1-week follow-up period
- Sitagliptin 100 mg + metformin (Type: ACTIVE_COMPARATOR): 2-week screening period, 26-week treatment duration, and a 1-week follow-up period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary kidney transplant~* Treatment with mycophenolic acid (MMF 1 g/d or EC-MPS 720 mg/d) and tacrolimus (trough concentration \[C0\] ≥ 5.5 ng/mL)~* Creatinine clearance ≥ 30 mL/min and \< 60 mL/min and stable renal function~Exclusion Criteria:~* Multi-organ recipients or previous transplant with any other organ different from kidney~* Biopsy proven acute rejection or treated acute rejection within the last 3 months.~* Prescription of mycophenolate mofetil 1 g/d or mycophenolate sodium 720 mg/d due to adverse event occurrence when higher doses were administered~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard dose EC-MPS (Type: ACTIVE_COMPARATOR): Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
- High EC-MPS (Type: EXPERIMENTAL): Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing dialysis or plan to start dialysis before the initial administration of the study medication~Exclusion Criteria:~* Patients with severe hypocalcemia (adjusted serum calcium level of \<7.5 mg/dL)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has a requirement for surgical intervention within 24 hours of study entry~* Requirement of antibacterial therapy in addition to surgical intervention in certain intra-abdominal infections~Exclusion Criteria:~* Female patients who are pregnant, nursing, or if of child bearing potential not using a medically accepted, effective method of birth control~* Any rapidly-progressing disease or immediately life-threatening illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven cancer of the head and neck cancer~* Stage 3 or 4~* Planned primary or adjuvant chemoradiation therapy~* Willing and able to provide informed consent~* English speaking~Exclusion Criteria:~* Currently on gabapentin~* Prior non-tolerance of gabapentin~* History of seizure disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I Standard of Care (Type: ACTIVE_COMPARATOR): Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
- Arm II Standard of Care Plus Gabapentin (Type: EXPERIMENTAL): Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with documented chronic genotype 2, 3, 4, 5 or 6 hepatitis C virus (HCV) infection~* Participants who have never received treatment for their HCV infection~* Participants with either no cirrhosis or up to Child Pugh A liver disease~* Participants with plasma HCV genotype level of more than or equal to 100, 000 IU/mL at screening~Exclusion Criteria:~* Evidence of Child Pugh B or C liver disease at screening, decompensated liver disease defined as prior or current history of ascities, hepatic encephalopathy, esophageal or gastric varices~* Participants with diagnosed or suspected hepatocellular carcinoma~* Participants coinfected with human immunodeficiency virus type 1 or 2, or hepatitis A or B virus infection or active tuberculosis at screening~* Participants with any active clinically significant disease, or medical history or physical examination or electrocardiogram findings during screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Genotype 2 (Type: EXPERIMENTAL): Participants with chronic genotype 2 hepatitis C virus (HCV) infection
- Genotype 3 (Type: EXPERIMENTAL): Participants with chronic genotype 3 HCV infection
- Genotype 4 (Type: EXPERIMENTAL): Participants with chronic genotype 4 HCV infection
- Genotype 5 (Type: EXPERIMENTAL): Participants with chronic genotype 5 HCV infection
- Genotype 6 (Type: EXPERIMENTAL): Participants with chronic genotype 6 HCV infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine, Placebo and Parent Management Training in Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Children 5 yrs to 14 years 11 mos with clinical diagnosis of Autism, Asperger's Disorder, or PDDNOS based upon the ADI-R and clinical evaluation by DSM-IV criteria,~* Mental age equal to or greater than 24 months,~* ADHD symptoms based upon the CASI and clinical confirmed diagnosis,~* CGIS-S rating of 4 or grater for ADHD symptoms,~* A mean item score of \>1.5 on both the Parent and Teacher (non-parent caregiver) SNAP-IV 18 ADHD symptoms or the 9-symptom hyperactive-impulsive subscale (symptoms must be cross-situational),~* Reliable care provider available to bring subject to clinic visits and weekly sessions.~Exclusion Criteria:~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder psychotic disorder NOS,bipolar disorder, or major depression (if accompanied by a family history of bipolar disorder) based upon evidence of suicidality, CASI, and clinical interview/history,~* Prior failed adequate trial of atomoxetine,~* Use of other psychotropic medications that produce CNS effects,~* Diagnosis of bipolar disorder, major depression, hypertension, cardiovascular disease, narrow angle glaucoma, other significant physical illness,~* Pregnancy or sexually active females (intercourse in the past 6 months, reported by either the subject or caregiver),~* Currently on effective medication treatment for ADHD,~* Prior involvement in Parent Management Training or other similar program,~* Currently on albuterol or taking beta blockers,~* Taking supplements or other complementary medical treatments where dose cannot be held at current level for duration of study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Atomoxetine + Parent Management Training
- 2 (Type: ACTIVE_COMPARATOR): Atomoxetine without Parent Management Training
- 3 (Type: PLACEBO_COMPARATOR): Placebo + Parent Management Training
- 4 (Type: PLACEBO_COMPARATOR): Placebo without Parent Management Training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>/=18 years~* First chronic phase, less than 6 months of duration~* Intermediate Sokal's risk~* Ph positive~* No previous treatment or hydroxiurea only.~* Performance status (ECOG/WHO) \< or = 2~* Written informed consent~Exclusion Criteria:~* Age \<18~* Low or high Sokal risk score.~* More than 6 months from diagnosis.~* Second chronic, accelerated or blastic phase~* Scheduled allogeneic stem cell transplantation within 1 year from diagnosis.~* Performance status (ECOG/WHO) \> 2 (see Appendix 2)~* Inability to provide written informed consent~* Pregnancy~* Formal refusal of any recommendation of a safe contraception~* Alcohol or drug addiction~* Altered hepatic or renal function as defined by AST/ALT or bilirubine \> 3 times upper normal limits (UNL) and by creatinine ³ 20mg/L Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet all the following criteria:~1. Patients that will come with a minimum 24-hour schedule of mechanical ventilation (MV)~2. Patients men and women\> 18 years and \<85 years~3. Patients speak and / or understand the Castilian / Catalan~4. Patients with hemodynamic and respiratory stability enough, that allows mobilization procedure turn.~5. Patients who have a carer / guardian giving consent to participate in the study~Exclusion Criteria:~The subjects presenting one or more of the following criteria are NOT eligible to participate in this study:~1. Patients with known hypersensitivity to fentanyl and muscle relaxants~2. Patients who are receiving a neuromuscular blocking Neurocritical~3. Patients serious (TCE and / or other severe neurological injury (Glasgow \<8), increased intracranial pressure, peripheral neuropathy, quadriplegia)~4. Patients with brain death or vegetative state~5. Patients who have received some extra supplement opioids (morphine, Fentanest) bolus within 4 hours prior to the study.~6. Collaboration in the 30 days prior to any study either experimental drugs or devices.~7. Patients that potentially present alterations in the ability to understand when they are aware to understand the purpose of the study and to give informed consent in writing.~8. Patients undergoing treatment with Monoamine Oxidase Inhibitors~9. Women who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
- Fentanest (Type: EXPERIMENTAL): For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete